Focal adhesion kinase (FAK)
Focal adhesion kinase (FAK), also known as PTK2, is a non-receptor protein tyrosine kinase that functions as a central signaling node at focal adhesions, where cells attach to the extracellular matrix through integrins.
Focal adhesion kinase (FAK), also known as PTK2, is a non-receptor protein tyrosine kinase that functions as a central signaling node at focal adhesions, where cells attach to the extracellular matrix through integrins. It integrates mechanical cues and adhesion-dependent signals to regulate cell migration, survival, proliferation, cytoskeletal remodeling, and mechanotransduction. Through autophosphorylation and downstream signaling, FAK helps coordinate pathways such as RhoA/ROCK, YAP/TAZ, MAPK, and other adhesion-linked cascades.
In biomedical research, FAK is widely studied as a mediator of tumor progression, invasion, therapy resistance, and tissue mechanobiology. Recent studies in the provided context also place FAK in cartilage homeostasis under cyclic tensile stress, in viscoelasticity-dependent cell adhesion and migration, and in cancer-associated signaling axes including ITGA5-FAK in liver cancer and c-met/FAK-linked oncogenic signaling in lung cancer. Because of its position at the interface of adhesion and signaling, FAK is a frequent therapeutic target in oncology and regenerative medicine.
Where the papers sit
8 papers from the last 6 months study Focal adhesion kinase (FAK) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 1 human data · 5 preclinical · 2 unclassified
Themes one subject
Those 8 are all about one subject.
-
FAK Signaling and Therapeutics
FAK-linked extracellular-matrix and integrin signaling is being examined across cancer, fibrosis, inflammation, and tissue injury. In cancer, inhibitor discovery targets pancreatic and KRAS-mutant colorectal tumors, while ITGA5-FAK signaling is implicated in lenvatinib resistance in hepatocellular carcinoma. Defactinib and related compounds are also moving through pharmacokinetic characterization alongside medicinal-chemistry optimization. The set remains broad, with no single disease mechanism or therapeutic direction dominating.
Papers
The 8 papers from the last 6 months that study Focal adhesion kinase (FAK) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
FAK Signaling and Therapeutics (8)
- How far are we from multi-omics states to therapeutic targets in microsatellite-stable colorectal cancer? Cancer cell · 23 Oct 2026 PMID 42913634
- β-Myrcene alleviates atopic dermatitis-like inflammation and is associated with ECM-FAK/Src-YAP signaling during epidermal barrier repair. European journal of pharmacology · 16 Sept 2026 PMID 42749005
- Loss of LCN2 Function Ameliorates Glucocorticoid-Induced Muscle Atrophy via Remodeling the Extracellular Matrix. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 18 Aug 2026 PMID 42610529
- Simultaneous Estimation of Avutometinib and Defactinib in Rat Plasma by Using LC-MS/MS and Its Application to Pharmacokinetic Studies. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517868
- Scaffold hopping-directed design and discovery of N1-substituted aminopyrimidine-indole derivatives as FAK inhibitors with anti-pancreatic cancer activity. Bioorganic & medicinal chemistry · 23 Jul 2026 PMID 42492381
- The design and synthesis of highly efficient FAK inhibitor for the potential treatment of colorectal cancer harboring KRAS mutation. Bioorganic chemistry · 30 Jun 2026 PMID 42379010
- Renal tubular epithelial-derived Angptl4 promotes renal fibrosis by inducing tubular cell senescence. Biochemical and biophysical research communications · 14 Jun 2026 PMID 42289177
- RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. Molecular biomedicine · 22 May 2026 PMID 42171939
By study type
Human data, design not indexed (1)
- How far are we from multi-omics states to therapeutic targets in microsatellite-stable colorectal cancer? Cancer cell · 23 Oct 2026 PMID 42913634
Preclinical: animal, cell and lab studies (5)
- Simultaneous Estimation of Avutometinib and Defactinib in Rat Plasma by Using LC-MS/MS and Its Application to Pharmacokinetic Studies. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517868
- Scaffold hopping-directed design and discovery of N1-substituted aminopyrimidine-indole derivatives as FAK inhibitors with anti-pancreatic cancer activity. Bioorganic & medicinal chemistry · 23 Jul 2026 PMID 42492381
- The design and synthesis of highly efficient FAK inhibitor for the potential treatment of colorectal cancer harboring KRAS mutation. Bioorganic chemistry · 30 Jun 2026 PMID 42379010
- Renal tubular epithelial-derived Angptl4 promotes renal fibrosis by inducing tubular cell senescence. Biochemical and biophysical research communications · 14 Jun 2026 PMID 42289177
- RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. Molecular biomedicine · 22 May 2026 PMID 42171939
Unclassified: not yet indexed with MeSH (2)
- β-Myrcene alleviates atopic dermatitis-like inflammation and is associated with ECM-FAK/Src-YAP signaling during epidermal barrier repair. European journal of pharmacology · 16 Sept 2026 PMID 42749005
- Loss of LCN2 Function Ameliorates Glucocorticoid-Induced Muscle Atrophy via Remodeling the Extracellular Matrix. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 18 Aug 2026 PMID 42610529
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.